Phospholipids – Fosfontsiale Mono solution for iv. introduced. 250 mg /5 ml ampoules 5 pcs

$22.00

Description

Release form

5 ml in ampoules for medicines made of dark medical glass of grades  Ñœ   Ž-1 or  Ñœ   Ž-3 or of the 1st hydrolytic class according to ISO 9187.

5 or 10 ampoules in a blister pack of film polyvinyl chloride.

1, 2 blister packs of 5 ampoules or 1 blister pack of 10 ampoules together with instructions for use are placed in a pack of cardboard.

It is allowed to put a scarifier in a pack.

Pharmacological action of

The phospholipids contained in the preparation are similar in chemical structure to endogenous phospholipids, but far exceed them in the content of polyunsaturated (essential) fatty acids. These high-energy molecules are embedded primarily in the structure of cell membranes and facilitate the restoration of damaged liver tissues.

Phospholipids affect lipid metabolism by regulating lipoprotein metabolism, as a result of which neutral fats and cholesterol are converted into forms suitable for transport, especially due to the increased ability of high density lipoproteins (HDL) to attach cholesterol, and are intended for further oxidation. During the excretion of phospholipids through the biliary tract, the lithogenic index decreases and bile stabilizes.

Pharmacokinetics: Binding primarily to high-density lipoproteins, phosphatidylcholine enters, in particular, in liver cells.

The half-life of the choline component is 66 hours, for unsaturated fatty acids – 32 hours.

Indications

Fatty liver degeneration, acute and chronic hepatitis, liver cirrhosis, hepatic coma and precoma, pre- and postoperative treatment for surgical interventions in the hepatobiliary zone, toxic liver damage

Pregnancy toxicosis

Psoriasis (as adjuvant therapy)

Radiation syndrome.

Contraindications

Hypersensitivity to the components of the drug

Soy intolerance

Children under 12 years.

Caution:

Pregnancy

Children over 12 years old.

Use during pregnancy and lactation

During pregnancy due to the presence of benzyl alcohol in the preparation, which can penetrate the placental barrier (the use of drugs containing gasoline alcohol in newborns or premature infants was associated with the development of dyspnea syndrome fatal), the use of the drug is possible only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

It is not recommended to use during breastfeeding due to the lack of data on the safety of the drug.

Special instructions

Use only clear solution!

Caution: The solution contains benzyl alcohol. For intravenous use only.

Children. The drug is used to treat children over 12 years old.

Impact on the ability to drive transp. Wed and fur. Not identified.

Composition of

1 ampoule contains:

Active ingredient:

Phospholipids (Lipoid C 100 *) – 266.00 mg, in terms of phosphatidylcholine – 250.00 mg.

Excipients:

Benzyl alcohol – 45.00 mg,

Deoxycholic acid – 126.50 mg,

Sodium hydroxide – 13.40 mg,

Sodium chloride – 12.00,

Riboflavin – not more than 0.50 mg,

Water for injection – up to 5 ml.

* Lipoid C 100 contains not more than 0.25% -tocopherol and not more than 0.2% ethanol.

Dosage and administration

Use only a clear solution.

Do not administer the drug intramuscularly due to a possible local reaction.

The drug is administered intravenously slowly 5-10 ml per day, in severe cases from 10 to 20 ml per day. At a time, 10 ml of the drug is allowed to be administered. To dilute the drug, it is recommended to use the patient’s own blood in a ratio of 1: 1. The course of treatment is up to 10 days with the subsequent transition to pa oral forms of phosphatidylcholine.

Treatment of psoriasis begins with oral administration of phosphatidylcholine for 2 weeks. After that, 10 intravenous injections of 5 ml are recommended with the simultaneous administration of PUVA therapy. After the completion of the injection course, oral administration of phosphatidylcholine is resumed.

In cases where it is impossible to use the patient s own blood to dilute the drug, electrolyte-free solutions should be used – 5% or 10% glucose solution, 5% xylitol solution in a 1: 1 ratio.

Side effects of

From the gastrointestinal tract: discomfort in the epigastric region, loose stools, nausea, gastralgia.

On the part of the immune system: allergic reactions (rash, exanthema, urticaria, pruritus).

Drug Interactions

Interactions with other drugs have not been studied.

The drug is not compatible with electrolyte solutions.

Do not administer the drug with other medicines in the same syringe.

Overdose

There have been no reports of overdose.

Storage Conditions

At 2 ° C to 8 ° C in the manufacturer’s packaging.

Keep out of the reach and sight of children.

Expiration

2 years.

Effective substance

Phospholipids

lekarstvennaja form

ampul